
    
      This is a multi-center, open-label, Phase I study of Obatoclax administered in combination
      with bortezomib in 3-week cycles to patients with relapsed or refractory Mantle Cell
      Lymphoma. Treatment may be administered on an outpatient basis. No investigational or
      commercial agents or therapies other than those described herein may be administered with the
      intent to treat the patients's malignancy. Supportive care measures including those directed
      at controlling symptoms resulting from Mantle Cell Lymphoma are allowed.
    
  